Patient preference for chronic insomnia treatment
Understanding patients’ needs and treatment preferences can help guide treatment selection. According to data collected from 602 patients with chronic insomnia enrolled in two phase III clinical trials, the most important drivers for patient treatment preference were found to be:17
daytime functioning
withdrawal symptoms
likelihood of abnormal thoughts and behaviour changes
Less important determinants were:17
daytime dizziness
likelihood of falls in the night
total time to fall and stay asleep
Functional endpoints, such as daytime functioning, should be considered when evaluating the efficacy and safety profile of insomnia treatments.17
Ready for the next step?
Treatment options for chronic insomnia
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.16
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- Stinson K, Tang N K, Harvey A G. Barriers to treatment seeking in primary insomnia in the United Kingdom: a cross-sectional perspective. Sleep 2006;29(12):1643-1646
- O’Regan D, Garcia-Borreguero D et al. Mapping the insomnia patient journey in Europe and Canada. Front Public Health 2023;11:1233201
- Hafner M, Romanelli R J et al. The societal and economic burden of insomnia in adults: an international study. RAND Corporation, 2023
- Moghe R, My Cheung J et al. Consumers using the internet for insomnia information: the who, what, and why. Sleep and Biological Rhythms 2014;12:297-304
- Cheung J M Y, Jarrin D C et al. Patterns of concomitant prescription, over-the-counter and natural sleep aid use over a 12-month period: a population based study. Sleep 2021;44(11):zsab141
- Gittins R, Missen L, Maidment I. Misuse of over the counter and prescription only medication by adults accessing specialist treatment services in the uk: a narrative synthesis. Subst Abuse 2022;16:11782218221111833
- Burns C. Rise in antihistamine-related deaths prompts call for move to POM status. The Pharmaceutical Journal 2021;306(7947); doi: 10.1211/PJ.2021.1.70125
- Ogeil R P, Chakraborty S P et al. Clinician and patient barriers to the recognition of insomnia in family practice: a narrative summary of reported literature analysed using the theoretical domains framework. BMC Fam Pract 2020;21(1):1
- Davy Z, Middlemass J, Siriwardena A N. Patients’ and clinicians’ experiences and perceptions of the primary care management of insomnia: qualitative study. Health Expect 2015;18(5):1371-1383
- National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Insomnia. Scenario: managing long-term insomnia (more than 3 months duration), May 2025. Available at: cks.nice.org.uk. Accessed August 2025
- Mignot E, Mayleben D et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 2022;21(2):125-139
- M3 Idorsia insomnia market research. May 2022 GP Omnibus results (N=1, 002 UK GPs; update 22 June 2022)
- Koffel E, Bramoweth A D, Ulmer C S. Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review. J Gen Intern Med 2018;33(6):955-962
- National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Scenario: managing short-term insomnia (less than 3 months duration), May 2025. Available at: cks.nice.org.uk. Accessed August 2025
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 922. Daridorexant for treating long‑term insomnia, 18 October 2023. Available at: nice.org.uk. Accessed August 2025
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
- Heidenreich S, Ross M et al. Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials. Sleep 2022;45(11):zsac204
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00656 | Date of preparation: September 2025
